NEOS Investment Management LLC Has $12.57 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

NEOS Investment Management LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 30.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,650 shares of the biopharmaceutical company’s stock after acquiring an additional 4,140 shares during the period. NEOS Investment Management LLC’s holdings in Regeneron Pharmaceuticals were worth $12,573,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Great Valley Advisor Group Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 5.0% in the 3rd quarter. Great Valley Advisor Group Inc. now owns 442 shares of the biopharmaceutical company’s stock valued at $465,000 after purchasing an additional 21 shares in the last quarter. Kingsview Wealth Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 2.6% during the 3rd quarter. Kingsview Wealth Management LLC now owns 860 shares of the biopharmaceutical company’s stock worth $904,000 after buying an additional 22 shares during the last quarter. Larson Financial Group LLC boosted its stake in Regeneron Pharmaceuticals by 127.3% in the third quarter. Larson Financial Group LLC now owns 50 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 28 shares in the last quarter. Independent Advisor Alliance bought a new position in Regeneron Pharmaceuticals in the third quarter valued at about $231,000. Finally, Truvestments Capital LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter worth about $39,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $640.14 on Thursday. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company’s fifty day simple moving average is $685.91 and its 200 day simple moving average is $805.04. Regeneron Pharmaceuticals, Inc. has a 12-month low of $629.02 and a 12-month high of $1,211.20. The firm has a market cap of $69.98 billion, a price-to-earnings ratio of 16.72, a PEG ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter last year, the firm posted $11.86 earnings per share. The firm’s revenue was up 10.3% on a year-over-year basis. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.55%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Wells Fargo & Company reduced their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the company from $1,130.00 to $738.00 in a research report on Thursday, January 16th. BMO Capital Markets lowered their price target on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a report on Tuesday, February 4th. Truist Financial dropped their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. Finally, Leerink Partnrs upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.